Translation of clinical trial outcomes to metastatic colorectal cancer patients in community practice

Sheau Wen Lok, Hui-Li Wong, Suzanne Kosmider, Kathryn Field, Jeanne Tie, Jayesh Desai, Susie Bae, Mark Tacey, Iain Skinner, Ian Jones, Peter Gibbs

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)

Abstract

Aim: As multiple new agents have been added to the treatment options for patients with metastatic colorectal cancer, survival outcomes in clinical trials have continued to improve. Similarly, improved outcomes in routine clinical care would be anticipated, but have yet to be demonstrated. Here, we aim to explore whether survival gains demonstrated in clinical trials are reproducible in routine practice, and whether factors beyond new therapies may be contributing to improved outcomes. Methods: Comparison of comprehensive treatment and outcome data for consecutive patients diagnosed in 2003-2006 versus 2007-2010 at four specialist hospitals in Australia. Results: Data were available on 965 patients; median age 66.1 years (range 19-93), 572 (59%) were male. For the latter time period, there was an increase in patients receiving any treatment (74% vs 66%, P=0.014), initial combination chemotherapy (57% vs 44%, P<0.001) and bevacizumab (15% vs 2%, P<0.001). There was no change in the percentage undergoing resection of distant metastatic disease. For the latter time period, overall survival was improved (median 24.8 vs 17.4 months, P<0.001), including patients not receiving any active treatment (11.9 vs 6.4 months, P=0.014). Conclusion: Survival outcomes in routine clinical care for patients with metastatic colorectal cancer have markedly improved in recent years following the introduction of multiple new active therapies. The improved outcome of untreated patients suggests earlier diagnosis and improved supportive care may also be contributing to survival gains.

Original languageEnglish
Pages (from-to)361-367
Number of pages7
JournalAsia-Pacific Journal of Clinical Oncology
Volume10
Issue number4
DOIs
Publication statusPublished - Dec 2014
Externally publishedYes

Keywords

  • Chemotherapy
  • Clinical characteristic
  • Colorectal cancer
  • Survival

Cite this

Lok, Sheau Wen ; Wong, Hui-Li ; Kosmider, Suzanne ; Field, Kathryn ; Tie, Jeanne ; Desai, Jayesh ; Bae, Susie ; Tacey, Mark ; Skinner, Iain ; Jones, Ian ; Gibbs, Peter. / Translation of clinical trial outcomes to metastatic colorectal cancer patients in community practice. In: Asia-Pacific Journal of Clinical Oncology. 2014 ; Vol. 10, No. 4. pp. 361-367.
@article{35c26040749242a685da6cef40a0d611,
title = "Translation of clinical trial outcomes to metastatic colorectal cancer patients in community practice",
abstract = "Aim: As multiple new agents have been added to the treatment options for patients with metastatic colorectal cancer, survival outcomes in clinical trials have continued to improve. Similarly, improved outcomes in routine clinical care would be anticipated, but have yet to be demonstrated. Here, we aim to explore whether survival gains demonstrated in clinical trials are reproducible in routine practice, and whether factors beyond new therapies may be contributing to improved outcomes. Methods: Comparison of comprehensive treatment and outcome data for consecutive patients diagnosed in 2003-2006 versus 2007-2010 at four specialist hospitals in Australia. Results: Data were available on 965 patients; median age 66.1 years (range 19-93), 572 (59{\%}) were male. For the latter time period, there was an increase in patients receiving any treatment (74{\%} vs 66{\%}, P=0.014), initial combination chemotherapy (57{\%} vs 44{\%}, P<0.001) and bevacizumab (15{\%} vs 2{\%}, P<0.001). There was no change in the percentage undergoing resection of distant metastatic disease. For the latter time period, overall survival was improved (median 24.8 vs 17.4 months, P<0.001), including patients not receiving any active treatment (11.9 vs 6.4 months, P=0.014). Conclusion: Survival outcomes in routine clinical care for patients with metastatic colorectal cancer have markedly improved in recent years following the introduction of multiple new active therapies. The improved outcome of untreated patients suggests earlier diagnosis and improved supportive care may also be contributing to survival gains.",
keywords = "Chemotherapy, Clinical characteristic, Colorectal cancer, Survival",
author = "Lok, {Sheau Wen} and Hui-Li Wong and Suzanne Kosmider and Kathryn Field and Jeanne Tie and Jayesh Desai and Susie Bae and Mark Tacey and Iain Skinner and Ian Jones and Peter Gibbs",
year = "2014",
month = "12",
doi = "10.1111/ajco.12260",
language = "English",
volume = "10",
pages = "361--367",
journal = "Asia-Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "Wiley-Blackwell",
number = "4",

}

Lok, SW, Wong, H-L, Kosmider, S, Field, K, Tie, J, Desai, J, Bae, S, Tacey, M, Skinner, I, Jones, I & Gibbs, P 2014, 'Translation of clinical trial outcomes to metastatic colorectal cancer patients in community practice', Asia-Pacific Journal of Clinical Oncology, vol. 10, no. 4, pp. 361-367. https://doi.org/10.1111/ajco.12260

Translation of clinical trial outcomes to metastatic colorectal cancer patients in community practice. / Lok, Sheau Wen; Wong, Hui-Li; Kosmider, Suzanne; Field, Kathryn; Tie, Jeanne; Desai, Jayesh; Bae, Susie; Tacey, Mark; Skinner, Iain; Jones, Ian; Gibbs, Peter.

In: Asia-Pacific Journal of Clinical Oncology, Vol. 10, No. 4, 12.2014, p. 361-367.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Translation of clinical trial outcomes to metastatic colorectal cancer patients in community practice

AU - Lok, Sheau Wen

AU - Wong, Hui-Li

AU - Kosmider, Suzanne

AU - Field, Kathryn

AU - Tie, Jeanne

AU - Desai, Jayesh

AU - Bae, Susie

AU - Tacey, Mark

AU - Skinner, Iain

AU - Jones, Ian

AU - Gibbs, Peter

PY - 2014/12

Y1 - 2014/12

N2 - Aim: As multiple new agents have been added to the treatment options for patients with metastatic colorectal cancer, survival outcomes in clinical trials have continued to improve. Similarly, improved outcomes in routine clinical care would be anticipated, but have yet to be demonstrated. Here, we aim to explore whether survival gains demonstrated in clinical trials are reproducible in routine practice, and whether factors beyond new therapies may be contributing to improved outcomes. Methods: Comparison of comprehensive treatment and outcome data for consecutive patients diagnosed in 2003-2006 versus 2007-2010 at four specialist hospitals in Australia. Results: Data were available on 965 patients; median age 66.1 years (range 19-93), 572 (59%) were male. For the latter time period, there was an increase in patients receiving any treatment (74% vs 66%, P=0.014), initial combination chemotherapy (57% vs 44%, P<0.001) and bevacizumab (15% vs 2%, P<0.001). There was no change in the percentage undergoing resection of distant metastatic disease. For the latter time period, overall survival was improved (median 24.8 vs 17.4 months, P<0.001), including patients not receiving any active treatment (11.9 vs 6.4 months, P=0.014). Conclusion: Survival outcomes in routine clinical care for patients with metastatic colorectal cancer have markedly improved in recent years following the introduction of multiple new active therapies. The improved outcome of untreated patients suggests earlier diagnosis and improved supportive care may also be contributing to survival gains.

AB - Aim: As multiple new agents have been added to the treatment options for patients with metastatic colorectal cancer, survival outcomes in clinical trials have continued to improve. Similarly, improved outcomes in routine clinical care would be anticipated, but have yet to be demonstrated. Here, we aim to explore whether survival gains demonstrated in clinical trials are reproducible in routine practice, and whether factors beyond new therapies may be contributing to improved outcomes. Methods: Comparison of comprehensive treatment and outcome data for consecutive patients diagnosed in 2003-2006 versus 2007-2010 at four specialist hospitals in Australia. Results: Data were available on 965 patients; median age 66.1 years (range 19-93), 572 (59%) were male. For the latter time period, there was an increase in patients receiving any treatment (74% vs 66%, P=0.014), initial combination chemotherapy (57% vs 44%, P<0.001) and bevacizumab (15% vs 2%, P<0.001). There was no change in the percentage undergoing resection of distant metastatic disease. For the latter time period, overall survival was improved (median 24.8 vs 17.4 months, P<0.001), including patients not receiving any active treatment (11.9 vs 6.4 months, P=0.014). Conclusion: Survival outcomes in routine clinical care for patients with metastatic colorectal cancer have markedly improved in recent years following the introduction of multiple new active therapies. The improved outcome of untreated patients suggests earlier diagnosis and improved supportive care may also be contributing to survival gains.

KW - Chemotherapy

KW - Clinical characteristic

KW - Colorectal cancer

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84910001518&partnerID=8YFLogxK

U2 - 10.1111/ajco.12260

DO - 10.1111/ajco.12260

M3 - Article

VL - 10

SP - 361

EP - 367

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

SN - 1743-7555

IS - 4

ER -